Serum Inflammatory Dynamics as Novel Biomarkers for Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer With Bone Metastases

被引：0

作者：

Asano, Yohei ^{[1
]}

Yamamoto, Norio ^{[1
]}

Hayashi, Katsuhiro ^{[1
]}

Takeuchi, Akihiko ^{[1
]}

Kato, Satoshi ^{[1
]}

Miwa, Shinji ^{[1
]}

Okuda, Miho ^{[2
]}

Matsumoto, Isao ^{[3
]}

Yano, Seiji ^{[4
]}

Demura, Satoru ^{[1
]}

机构：

[1] Kanazawa Univ, Grad Sch Med Sci, Dept Orthopaed Surg, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan

[2] Kanazawa Univ, Grad Sch Med Sci, Dept Radiol, Kanazawa, Ishikawa, Japan

[3] Kanazawa Univ Hosp, Dept Thorac Surg, Kanazawa, Ishikawa, Japan

[4] Kanazawa Univ Hosp, Dept Resp Med, Kanazawa, Ishikawa, Japan

来源：

ANTICANCER RESEARCH | 2024年 / 44卷 / 10期

关键词：

Non-small-cell lung cancer; immune checkpoint inhibitor; neutrophil-to-lymphocyte ratio; c-reactive protein; bone metastasis; TO-LYMPHOCYTE RATIO; NIVOLUMAB; DOCETAXEL; PROGNOSIS; SURVIVAL; PEMBROLIZUMAB; ASSOCIATION; EFFICACY; MARKERS; PREDICT;

D O I：

10.21873/anticanres.17278

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The aim of the study was todevelopanovelpredictivescoringsystembasedonthedynamicsofseruminflammatoryindicatorsinimmunecheckpointinhibitor(ICI)treatmentonnon-small-celllungcancer(NSCLC)withbonemetastases. Patients and Methods:SixtypatientswithNSCLCandbonemetastasestreatedwithICIsbetweenJanuary2016andMarch2021wereincludedinthedevelopmentcohort.Serumneutrophil-to-lymphocyteratio(NLR)andC-reactiveprotein(CRP)levelswereassessedbefore(pre-value)and6weeksafter(post-value)ICItreatment,andanovelpredictivescorewasdeveloped:pre-value >= post-value,0points;pre-value1point;totalscore:0-2points.Theassociationsofthesedynamicsandthescorewithclinicaloutcomes,includingoverallsurvival(OS),progression-freesurvival(PFS),responserate(RR)ofbonemetastases,anddiseasecontrolrate(DCR),wereevaluated.Furthermore,cross-validationwasperformedwith23patientsafterApril2021usingthesameinclusioncriteria.Results:ThepatientswithdecreasedseruminflammationlevelshadsignificantlybetterOS,PFS,andRRthanthosewithincreasedlevels.Applyingthedevelopedscoretothedevelopmentcohort,thepatientswith0pointshadsignificantlybetterOS,PFS,andRRthanothers.Inmultivariableanalysis,thescoreindependentlypredictedtreatmentresponsetoICIforbonemetastasisand prognosis.Cross-validationshowedthatOS,PFS,andRRweresignificantlybetterinthepatientsinthe0-pointgroup. Conclusion:TheearlyNLRandCRPdynamicswereassociatedwiththerapeuticresponsestoICIsinNSCLCwithbonemetastases.Ournovelscoringsystembasedonthesedynamicsissimple and has a high predictive accuracy

引用

页码：4493 / 4503

页数：11

共 51 条

[1] Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis [J].

Asano, Yohei ;

Yamamoto, Norio ;

Demura, Satoru ;

Hayashi, Katsuhiro ;

Takeuchi, Akihiko ;

Kato, Satoshi ;

Miwa, Shinji ;

Igarashi, Kentaro ;

Higuchi, Takashi ;

Taniguchi, Yuta ;

Morinaga, Sei ;

Sone, Takashi ;

Okuda, Miho ;

Matsumoto, Isao ;

Yano, Seiji ;

Tsuchiya, Hiroyuki .

CANCER MEDICINE, 2023, 12 (11) :12425-12437

[2] The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer [J].

Asano, Yohei ;

Yamamoto, Norio ;

Demura, Satoru ;

Hayashi, Katsuhiro ;

Takeuchi, Akihiko ;

Kato, Satoshi ;

Miwa, Shinji ;

Igarashi, Kentaro ;

Higuchi, Takashi ;

Yonezawa, Hirotaka ;

Araki, Yoshihiro ;

Morinaga, Sei ;

Saito, Shiro ;

Sone, Takashi ;

Kasahara, Kazuo ;

Tsuchiya, Hiroyuki .

FRONTIERS IN ONCOLOGY, 2022, 12

[3] Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio [J].

Bongiovanni, Alberto ;

Foca, Flavia ;

Menis, Jessica ;

Stucci, Stefania Luigia ;

Artioli, Fabrizio ;

Guadalupi, Valentina ;

Forcignano, Maria Rosachiara ;

Fantini, Manuela ;

Recine, Federica ;

Mercatali, Laura ;

Spadazzi, Chiara ;

Burgio, Marco Angelo ;

Fausti, Valentina ;

Miserocchi, Anna ;

Ibrahim, Toni .

FRONTIERS IN IMMUNOLOGY, 2021, 12

[4] Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer [J].

Booka, Eisuke ;

Kikuchi, Hirotoshi ;

Haneda, Ryoma ;

Soneda, Wataru ;

Kawata, Sanshiro ;

Murakami, Tomohiro ;

Matsumoto, Tomohiro ;

Hiramatsu, Yoshihiro ;

Takeuchi, Hiroya .

ANTICANCER RESEARCH, 2022, 42 (06) :2977-2987

[5] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[6] A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab [J].

Botticelli, Andrea ;

Salati, Massimiliano ;

Di Pietro, Francesca Romana ;

Strigari, Lidia ;

Cerbelli, Bruna ;

Zizzari, Ilaria Grazia ;

Giusti, Raffaele ;

Mazzotta, Marco ;

Mazzuca, Federica ;

Roberto, Michela ;

Vici, Patrizia ;

Pizzuti, Laura ;

Nuti, Marianna ;

Marchetti, Paolo .

JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)

[7] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[8] The causes and consequences of genetic heterogeneity in cancer evolution [J].

Burrell, Rebecca A. ;

McGranahan, Nicholas ;

Bartek, Jiri ;

Swanton, Charles .

NATURE, 2013, 501 (7467) :338-345

[9] Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer [J].

Chen, Yuzhong ;

Wen, Shaodi ;

Xia, Jingwei ;

Du, Xiaoyue ;

Wu, Yuan ;

Pan, Banzhou ;

Zhu, Wei ;

Shen, Bo .

FRONTIERS IN IMMUNOLOGY, 2021, 12

[10] Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients [J].

De Giglio, Andrea ;

Deiana, Chiara ;

Di Federico, Alessandro .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (05) :1835-1847

← 1 2 3 4 5 6 →